PATENT CLAIM ANALYSIS

Application Number: 15751563
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "568000"]

Abstract:
The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of  cannabis  such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.

Claim (Index 10):
The method according to  claim 9 , wherein the CBDA:CBD ratio is in the range of from 9:1 to 1:9 (CBDA:CBD).

Metadata:
- Claim Count in Document: 5.0
- Percentile: 88.0
- Lexical Diversity: 1.91026
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14881969', '15449402', '15449535', '16090039', '13075873']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.782559550956837
- 35 USC 102 Novelty (BERT): 0.5497224835749166
- Combined Prediction Score: 0.759275844218645
- Mean Citation Score: 375.670264
- Max Citation Score: 386.8956
- Similarity Product: 280.7723126764298

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test